ClinicalTrials.gg
CompletedNCT00594984Updated Nov 4, 2015

Phase I/II Combination With Irinotecan- Erbitux

A Phase 1/2 interventional study of Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MCRC), sponsored by Bristol-Myers Squibb. Completed at 12 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-04.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
119th of 185
38 · median 60
Started
2008
with 7 others
Phase 1/2
20 of 187
6 open now
Registered
58th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 119th largest by enrollment of the 185 interventional ones that give a count, is one of 8 that started in 2008, is one of 20 in phase 1/2, and was the 58th registered.

Colorectal Neoplasms

6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC)

Part 2: To compare median duration of progression free survival (PFS)

03

Conditions studied

  • Metastatic Colorectal Cancer (MCRC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven MCRC
  • Prior irinotecan allowed
  • Prior Erbitux allowed

Exclusion criteria

Exclusion Criteria:

  • No prior brivanib
  • No prior combination of irinotecan with Erbitux
  • No secondary
  • No anti-coagulation therapy
  • No prior history of blood clots requiring anti-coagulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    Arm 1 - Phase 1

    Cetuximab + Irinotecan + Brivanib OR Cetuximab + Irinotecan + Brivanib Placebo

    Drug: Cetuximab · Drug: Irinotecan · Drug: Brivanib · Drug: Brivanib Placebo

  • Placebo comparator
    Arm 2 - Phase 2

    Cetuximab + Irinotecan + Brivanib OR Cetuximab + Irinotecan + Brivanib Placebo

    Drug: Cetuximab · Drug: Irinotecan · Drug: Brivanib · Drug: Brivanib Placebo

Interventions

  • IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression

    Also known as: Erbitux, BMS-564717

  • IV solution, IV, Q3W, 350 mg/m2, until progression

  • Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression

  • Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression

  • DrugBrivanib Placebo

    Oral, tablet, QD, until progression

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics and markers of exploratory coagulation pathways will be conducted during this trial

    Time frame: PK C1D1-C2-D3, biomarker throughout the study

  2. Safety and tolerability of interventions will be collected

    Time frame: throughout the study on Part II

Secondary outcomes

  1. Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects

    Time frame: throughout the study on Part II

07

Study locations

12 sites
  • Usc/Norris Comprehensive Cancer Center Hospital
    Los Angeles, California 90033, United States
  • Usc/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Local Institution
    Buenos Aires, C1426ANZ, Argentina
  • Local Institution
    Odense C, 5000, Denmark
  • Local Institution
    Meldola Fc, 47014, Italy
  • Local Institution
    Milano, 20141, Italy
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Madrid, 28050, Spain
  • Local Institution
    Stockholm, 17176, Sweden
  • Local Institution
    Uppsala, 75185, Sweden
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2008
First posted
Jan 16, 2008
Start
May 2008
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results delay requested
Sep 23, 2015
Last update
Nov 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00594984
Responsible party
Sponsor
First posted
Jan 16, 2008
Start date
May 2008
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Nov 4, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Irinotecan · Brivanib

Start the discussion